HK1114374A1 - Pyrazolylaminopyridine derivatives useful as kinase inhibitors - Google Patents
Pyrazolylaminopyridine derivatives useful as kinase inhibitorsInfo
- Publication number
- HK1114374A1 HK1114374A1 HK08101578.0A HK08101578A HK1114374A1 HK 1114374 A1 HK1114374 A1 HK 1114374A1 HK 08101578 A HK08101578 A HK 08101578A HK 1114374 A1 HK1114374 A1 HK 1114374A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- derivatives useful
- pyrazolylaminopyridine
- pyrazolylaminopyridine derivatives
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65005305P | 2005-02-04 | 2005-02-04 | |
| US65332905P | 2005-02-16 | 2005-02-16 | |
| US72163305P | 2005-09-29 | 2005-09-29 | |
| PCT/GB2006/000334 WO2006082392A1 (en) | 2005-02-04 | 2006-02-01 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1114374A1 true HK1114374A1 (en) | 2008-10-31 |
Family
ID=36177856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08101578.0A HK1114374A1 (en) | 2005-02-04 | 2008-02-13 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| HK12104298.7A HK1163677A1 (zh) | 2005-02-04 | 2012-05-02 | 可用作激酶抑制劑的吡唑基氨基吡啶衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK12104298.7A HK1163677A1 (zh) | 2005-02-04 | 2012-05-02 | 可用作激酶抑制劑的吡唑基氨基吡啶衍生物 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8324252B2 (pl) |
| EP (2) | EP1846394B1 (pl) |
| JP (1) | JP5139084B2 (pl) |
| KR (1) | KR101302945B1 (pl) |
| CN (1) | CN101155800B (pl) |
| AR (1) | AR056184A1 (pl) |
| AT (1) | ATE530545T1 (pl) |
| AU (1) | AU2006210710B2 (pl) |
| BR (1) | BRPI0606793A8 (pl) |
| CA (1) | CA2595834C (pl) |
| CY (2) | CY1115078T1 (pl) |
| DK (2) | DK1846394T3 (pl) |
| ES (2) | ES2375735T3 (pl) |
| HK (2) | HK1114374A1 (pl) |
| HR (1) | HRP20110962T1 (pl) |
| HU (1) | HUE025671T2 (pl) |
| IL (1) | IL184674A (pl) |
| ME (1) | ME02645B (pl) |
| MX (1) | MX2007009437A (pl) |
| MY (1) | MY149512A (pl) |
| NO (1) | NO341112B1 (pl) |
| NZ (1) | NZ561145A (pl) |
| PL (2) | PL1846394T3 (pl) |
| PT (2) | PT2383268E (pl) |
| RS (1) | RS52061B (pl) |
| SA (1) | SA06270007B1 (pl) |
| SI (2) | SI2383268T1 (pl) |
| TW (1) | TWI370127B (pl) |
| UY (1) | UY29360A1 (pl) |
| WO (1) | WO2006082392A1 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1853588E (pt) | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
| CA2608009A1 (en) * | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ES2391783T3 (es) | 2005-10-28 | 2012-11-29 | Astrazeneca Ab | Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer |
| EP2083624A4 (en) * | 2006-10-18 | 2010-06-16 | Merck Sharp & Dohme | 2-HYDROXY-2-PHENYL / THIOPHENYLPROPIONAMIDE AS ANDROGEN RECEPTOR MODULATORS |
| WO2008053812A1 (fr) * | 2006-10-27 | 2008-05-08 | Mitsubishi Tanabe Pharma Corporation | Dérivé de cyanopyridine et son utilisation médicale |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| JP5524491B2 (ja) * | 2008-03-04 | 2014-06-18 | 石原産業株式会社 | ３−アミノ−２−クロロ−６−トリフルオロメチルピリジンの製造方法 |
| TW201011017A (en) * | 2008-08-19 | 2010-03-16 | Astrazeneca Ab | Chemical compounds 495-1 |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| BR112012033770A2 (pt) * | 2010-06-30 | 2016-11-22 | Fujifilm Corp | novo derivado de nicotinamida ou sal do mesmo |
| UY33517A (es) | 2010-07-19 | 2012-02-29 | Astrazeneca Ab | Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?. |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| KR101744607B1 (ko) | 2011-12-28 | 2017-06-08 | 후지필름 가부시키가이샤 | 신규인 니코틴아미드 유도체 또는 그 염 |
| RU2014141674A (ru) | 2012-03-16 | 2016-05-10 | Аксикин Фармасьютикалз, Инк. | 3,5-диаминопиразоловые ингибиторы киназы |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| CN104812744B (zh) * | 2012-11-05 | 2017-12-01 | 爱默蕾大学 | 7,8‑二羟黄酮和7,8‑取代的黄酮衍生物、组合物及其相关方法 |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
| HUE059131T2 (hu) | 2014-08-11 | 2022-10-28 | Acerta Pharma Bv | BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja |
| UA118312C2 (uk) | 2014-12-23 | 2018-12-26 | Ексікін Фармасутікалз, Інк. | 3,5-діамінопіразолові інгібітори кінази |
| JP2019513700A (ja) | 2016-03-16 | 2019-05-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物 |
| CA3056970A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| EP3781565A1 (en) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020233645A1 (zh) | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
| US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| BR0013899A (pt) | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
| ATE449764T1 (de) | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
| CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
| JP4969010B2 (ja) | 2000-05-08 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖ複製阻害性ピリミジンのプロドラッグ |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| IL153325A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| JP2004507526A (ja) | 2000-08-31 | 2004-03-11 | ファイザー・プロダクツ・インク | ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用 |
| EP1339680A1 (en) | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| AU8664701A (en) | 2000-09-01 | 2002-03-22 | Glaxo Group Ltd | Oxindole derivatives |
| US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE318812T1 (de) | 2000-12-21 | 2006-03-15 | Bristol Myers Squibb Co | Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie |
| CN100436452C (zh) | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
| WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| EP1430053B1 (en) | 2001-09-27 | 2006-10-25 | SmithKline Beecham Corporation | AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN |
| SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| US20090227648A1 (en) * | 2004-04-21 | 2009-09-10 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
| AU2005289426A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CA2588220A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| PT1853588E (pt) * | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
| BRPI0608160A2 (pt) | 2005-02-16 | 2010-11-09 | Astrazeneca Ab | anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado |
| CN101208093A (zh) * | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 吡唑-嘧啶衍生物在治疗疼痛中的用途 |
| WO2006118231A1 (ja) | 2005-04-28 | 2006-11-09 | Mitsubishi Tanabe Pharma Corporation | シアノピリジン誘導体及びその医薬としての用途 |
| US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
| CA2608009A1 (en) * | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ES2391783T3 (es) * | 2005-10-28 | 2012-11-29 | Astrazeneca Ab | Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| JP2009541480A (ja) * | 2006-06-30 | 2009-11-26 | アストラゼネカ アクチボラグ | 癌の治療において有用なピリミジン誘導体 |
| TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
-
2006
- 2006-02-01 SI SI200631992T patent/SI2383268T1/sl unknown
- 2006-02-01 NZ NZ561145A patent/NZ561145A/en not_active IP Right Cessation
- 2006-02-01 PT PT111673620T patent/PT2383268E/pt unknown
- 2006-02-01 AT AT06701619T patent/ATE530545T1/de active
- 2006-02-01 HU HUE11167362A patent/HUE025671T2/en unknown
- 2006-02-01 PL PL06701619T patent/PL1846394T3/pl unknown
- 2006-02-01 ME MEP-2011-563A patent/ME02645B/me unknown
- 2006-02-01 SI SI200631240T patent/SI1846394T1/sl unknown
- 2006-02-01 ES ES06701619T patent/ES2375735T3/es active Active
- 2006-02-01 PL PL11167362T patent/PL2383268T3/pl unknown
- 2006-02-01 DK DK06701619.6T patent/DK1846394T3/da active
- 2006-02-01 BR BRPI0606793A patent/BRPI0606793A8/pt not_active IP Right Cessation
- 2006-02-01 ES ES11167362.0T patent/ES2555063T3/es active Active
- 2006-02-01 EP EP06701619A patent/EP1846394B1/en active Active
- 2006-02-01 WO PCT/GB2006/000334 patent/WO2006082392A1/en active Application Filing
- 2006-02-01 JP JP2007553688A patent/JP5139084B2/ja not_active Expired - Fee Related
- 2006-02-01 EP EP11167362.0A patent/EP2383268B1/en active Active
- 2006-02-01 US US11/815,140 patent/US8324252B2/en not_active Expired - Fee Related
- 2006-02-01 CN CN2006800101082A patent/CN101155800B/zh not_active Expired - Fee Related
- 2006-02-01 DK DK11167362.0T patent/DK2383268T3/en active
- 2006-02-01 KR KR1020077020258A patent/KR101302945B1/ko not_active IP Right Cessation
- 2006-02-01 AU AU2006210710A patent/AU2006210710B2/en not_active Ceased
- 2006-02-01 MX MX2007009437A patent/MX2007009437A/es active IP Right Grant
- 2006-02-01 CA CA2595834A patent/CA2595834C/en not_active Expired - Fee Related
- 2006-02-01 RS RS20110563A patent/RS52061B/en unknown
- 2006-02-01 PT PT06701619T patent/PT1846394E/pt unknown
- 2006-02-02 AR ARP060100376A patent/AR056184A1/es not_active Application Discontinuation
- 2006-02-03 UY UY29360A patent/UY29360A1/es not_active Application Discontinuation
- 2006-02-03 TW TW095103831A patent/TWI370127B/zh not_active IP Right Cessation
- 2006-02-03 MY MYPI20060475A patent/MY149512A/en unknown
- 2006-02-04 SA SA06270007A patent/SA06270007B1/ar unknown
-
2007
- 2007-07-17 IL IL184674A patent/IL184674A/en not_active IP Right Cessation
- 2007-07-20 NO NO20073791A patent/NO341112B1/no not_active IP Right Cessation
-
2008
- 2008-02-13 HK HK08101578.0A patent/HK1114374A1/xx not_active IP Right Cessation
-
2011
- 2011-12-21 HR HR20110962T patent/HRP20110962T1/hr unknown
-
2012
- 2012-01-11 CY CY20121100025T patent/CY1115078T1/el unknown
- 2012-05-02 HK HK12104298.7A patent/HK1163677A1/zh not_active IP Right Cessation
- 2012-11-29 US US13/688,790 patent/US8835465B2/en not_active Expired - Fee Related
-
2015
- 2015-11-26 CY CY20151101071T patent/CY1119077T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI370127B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| HK1114380A1 (en) | Pyrrolopyrazoles as kinase inhibitors | |
| IL186845A0 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| EP1954277A4 (en) | AMINOPYRIMIDINES SUITABLE AS KINASEINHIBITORS | |
| IL190078A0 (en) | Kinase inhibitors | |
| HK1117523A1 (en) | Substituted benzimidazoles as kinase inhibitors | |
| ZA200606683B (en) | Pyrazolotriazines as kinase inhibitors | |
| ZA200700181B (en) | Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors | |
| HK1107348A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| ZA200710343B (en) | Bicyclic derivatives as p38 kinase inhibitors | |
| PL1943243T3 (pl) | Inhibitory kinazy | |
| EP2046333A4 (en) | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE | |
| EP1778693A4 (en) | AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL | |
| IL188027A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
| HK1112918A1 (en) | Benzofuranyl derivatives as 5-ht6-receptor inhibitors | |
| ZA200800506B (en) | Substituted benzimidazoles as kinase inhibitors | |
| ZA200709732B (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| ZA200804599B (en) | Aminopyrimidines useful as kinase inhibitors | |
| ZA200706212B (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| EP1940411A4 (en) | MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | |
| IL189985A0 (en) | Kinase inhibitors | |
| ZA200803287B (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190130 |